Veterinary Practice EBITDA Multiples in 2026: A Vet’s Guide to What Practices Sell For

Key takeaways

• Vet practices in 2026 sell for 5 to 13 times normalized EBITDA (the practice’s pure operating profit, before taxes and accounting choices), depending on practice profile and sale process.
• Direct offers from a single private equity buyer typically clear meaningfully lower than what the same practice clears through a competitive process — the difference reliably runs into millions of dollars on any practice doing $1 million-plus in normalized EBITDA.
• A structured competitive process with multiple qualified bidders consistently produces meaningfully higher outcomes on the same practice. On a $1 million EBITDA practice, the difference between a 6x direct offer and an 11x competitive process outcome is $5 million in headline value.
• Specialty and emergency hospitals command meaningfully higher multiples than comparable general practice — typically 1 to 2.5 times more, with the strongest specialty platforms reaching even higher.
• The single largest variable in any sale is the process used to sell, not the practice itself.

There’s a moment in every practice sale I run that owners remember. Usually it’s somewhere around bid three or bid four.

The vet sitting across from me at dinner walked into the process expecting maybe $5 million or $6 million for the practice they spent 25 years building. The spreadsheet on the table now shows a number two or 3 million dollars higher than that.

They stare at me and ask if it’s real.

That moment is what this article is about. The gap between what a single private equity buyer will pay for your practice when they think they have no competition, and what the same buyer will pay when they know they do.

That gap is the entire reason this profession exists, and it’s the answer to almost every question about what your practice is worth.

I’ve written this guide to be the most thorough and honest answer you’ll find anywhere on what vet practices actually sell for in 2026. Not the press-release version.

The real one. By the end of it, you should know exactly where your specific practice would fall in the multiple range, what would move it up, and what process would clear the highest defensible number.

The math the way I’d explain it over dinner

Vet practices in 2026 sell for somewhere between 5 and 13 times their earnings. The technical term for that earnings number is EBITDA — earnings before interest, taxes, depreciation, and amortization.

In plain terms, it’s what your practice produces in pure operating profit, before you factor in how you finance the practice, what the IRS takes, or what your accountant writes off on paper as depreciation. The multiplier itself (the 5 to 13) is called the “multiple.” Buyers price your practice by multiplying your EBITDA by some multiple to set the headline number.

Where your specific practice lands in the 5-to-13 range depends partly on the practice itself. Doctor count.

How dependent the practice is on you personally. Growth rate.

Margin. Geography.

Specialty mix. Each of those moves the number a point or two on the multiplier.

If your practice produces $1 million in EBITDA, moving from a 7x multiple to a 9x multiple — what folks in this business call “two more additional multiples of EBITDA,” or “2 multiples” — adds 2 million dollars to the final price. The terms “additional multiples of EBITDA” and “turns” both mean the same thing: each one is a full multiple of your EBITDA in additional sale value.

But the largest single variable isn’t a property of your practice at all. It’s the process you use to sell it.

Direct conversations with one private equity-backed buyer routinely clear at the bottom of the range. Competitive processes with multiple bidders routinely clear at the top.

Direct, single-bidder offers from one private equity buyer come in meaningfully lower than what the same practice clears through a structured competitive process. The private credit research firm Octus’s 2025 observation captures the dynamic: in a single-bidder context, multiples for typical private veterinary practices were “lingering in the mid- to high single digits” through the first quarter of last year.

Those numbers describe what a financial buyer offers when nobody else is in the room — not what the practice is actually worth in a market with multiple qualified buyers competing.

Run that same practice through a structured competitive process — what we call the Elite Selling System — and the number moves. The name comes from how the process actually works.

We hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people. Across the deals we’ve closed over the past four-plus years through the Elite Selling System, the average multiple has come in at just over 10 times EBITDA.

In 2025 specifically, the average climbed past eleven, and the median deal cleared closer to thirteen. The first deals of 2026 are running in roughly that same range.

The arithmetic on the gap is sobering. On a practice doing $1 million in normalized EBITDA, the difference between a 6x direct offer and an 11x competitive close is 5 million dollars.

Same practice. Same week.

Same buyers, in some cases. Different process to find out who would actually pay the most.

Where 2026 multiples land by practice profile

Here’s the range table the way I’d walk an owner through it. I’ve split it into the direct-offer market (what one private equity buyer offers when they’re the only bidder) and the competitive-process range (what the same practice clears when multiple buyers compete).

Practice profile	Revenue	Normalized EBITDA	Direct-offer multiple	Competitive-process multiple
Solo, owner-dependent (owner produces 70%+)	Under $1.5M	Under $200K	4x to 6x	6x to 8x
Solo with one associate	$1.5M to $2.5M	$200K to $400K	5x to 7x	7x to 9x
Multi-doctor general practice, regional	$2.5M to $4.5M	$400K to $800K	5.5x to 7.5x	9x to 12x
Multi-doctor with sustained growth	$4.5M to $7M	$800K to $1.4M	7x to 9x	11x to 14x
Scaled multi-site or specialty/ER	$7M+	$1.4M+	9x to 12x	13x+

These ranges reconcile three underlying data sources. QuantPillar’s 2025-26 private markets valuation survey assigns the veterinary sub-sector a typical range of 8x to 14x EV/EBITDA, with the spread driven by scale and specialty mix. iVET360, the operations-analytics firm focused on companion animal practices, notes that high-performing practices typically transact at 8x to 13x.

Capstone Partners‘ deal-flow commentary anchors the lower bound of the direct-offer market at around 5.5x for the smaller multi-doc clinics actually closing this year. The competitive-process column reflects what we see in our own work and what other advisor-led processes tend to clear.

A reasonable owner reading that table will either land cleanly inside a row or sit between two rows. Either way, the multiple you actually realize at sale is more about which column you end up in (direct or competitive) than about which row your practice fits.

Wondering what range your specific practice falls into? Get a Free Practice Value Estimate — we’ll pull your numbers, normalize the EBITDA properly, identify the right buyer pool, and send you back a defensible value range with the math behind it. No upfront cost, no obligation.

A real example from our work

A 4-doctor mixed practice in a Midwestern suburban market — 75% small animal, 25% large animal — went to market through our process. The competitive bidding produced a final clearing price of over $12 million at an 11x EBITDA multiple, closed in 4 months.

The 11x reflects what a structured process can produce on a multi-doctor practice with the right buyer pool engaged in parallel.

What separates a 6x offer from an 11x offer

Five variables decide where any specific practice falls within its size band. I’ll walk through each in the order private equity buyers actually weight them — which is not the order most owners expect.

1. Doctor count and owner clinical dependence

When sophisticated buyers run the numbers on a practice, the first thing they look at isn’t revenue or margin. It’s how much of the clinical work runs through the owner personally.

If you’re producing 70 percent or more of the practice’s revenue as a working vet, you’re not selling a practice the next owner can step into. You’re selling a job — and the job goes away the day you walk out.

Buyers price that risk in. The penalty applied to owner-heavy practices is roughly 1 to 2 additional multiples of EBITDA, meaning a practice with diversified doctor production that would clear at 9 times earnings clears at 7 or 8 with concentrated production.

On a $1 million EBITDA practice, that gap is 1 to 2 million dollars of headline sale value.

An example from last year. A solo owner came to me running a beautiful practice — strong revenue, healthy margins, modern facility.

The challenge was that he was personally producing roughly four-fifths of the clinical work. The first direct offer he had received was meaningful but unimpressive.

We spent the better part of a year bringing in associates and systematically shifting his production share down. When we took the practice to market through a competitive process, it cleared a much better number — the kind of better that changes retirement plans.

Same building, same financials underneath. Different production profile, different buyer pool willing to compete.

The mechanism for reversing the discount is slow but reliable. Hiring associates doesn’t immediately credit the multiple — buyers want to see at least two and ideally three quarters of sustained associate production before they’ll factor it into the underwriting.

If you’re 24 months from selling, an associate hire now is meaningful. If you’re 12 months out, the calculus is tighter, and you may want to focus on other levers.

2. Growth trajectory

PE-backed buyers underwrite forward. They’re not paying for the revenue you produced last year.

They’re paying for the projected EBITDA they’ll inherit and grow over the next several years until they exit. A 3-year revenue compound annual growth rate above 5 percent earns a positive multiple adjustment.

Flat revenue subtracts at least a point. Declining revenue is brutal — sophisticated buyers will find a reason not to bid on it at all if they can.

The logic isn’t mysterious. When a financial buyer pays 10 times EBITDA today, they need that number to make sense after their own integration costs and the multiple they’ll exit at 3 to 7 years from now.

Growth supplies that math. Stagnation forces them to find growth through their own operating playbook, which is harder and riskier than buying it pre-built.

3. EBITDA margin

A practice running at 10 to 12 percent EBITDA margin signals operational inefficiency to buyers. They pull the multiple down to compensate.

The working norm for healthy companion-animal general practices is 15 to 22 percent. Practices that sustain above 20 percent earn the upper end of their size tier’s range.

iVET360 framed this in concrete terms in one of their published analyses, noting that a single year of operational restructuring lifted 1 practice’s estimated worth by roughly $1.65 million, almost entirely through margin expansion. The mechanics: cleaner inventory management, tightened technician utilization, better pricing discipline on services, reduced wasted CE budget.

None of those are dramatic — they’re operational habits — but they compound.

4. Management infrastructure

This is the variable owners most often underweight. A practice that depends on the owner’s daily attention to run isn’t a practice the buyer can plug into their portfolio.

It’s a job, and a fragile one. PE-backed buyers want a practice they can integrate without rebuilding the operating layer underneath it.

The discount applied to a practice that runs through the owner’s calendar versus one with a real practice manager, formal roles, and documented systems is roughly 1 to 2 additional multiples of EBITDA.

The investment to build management depth runs about 1 to 3 percent of revenue annually. On a $4 million revenue practice that’s somewhere between $40,000 and $120,000 a year.

The multiple uplift on a healthy mid-sized practice can be six or seven 100 thousand dollars per point. The math usually pays back many times over within the typical 18- to 24-month prep window.

5. Competitive process

Cover the first four variables and you’ve moved the multiple a few points. The fifth variable — running a competitive sale process versus accepting a direct offer — typically moves it more than the other four combined.

I’ve written about this enough that I won’t belabor it here, but the mechanics are these. Buyers offer their lowest defensible number when they don’t know who else is bidding.

A direct conversation with one private equity-backed buyer runs on the assumption that the seller will likely accept some version of the initial range. A competitive process flips the dynamic.

Now every buyer knows they have to bid against unknown alternatives, and their internal underwriting shifts upward. The buyers most willing to pay reveal themselves through the bidding rather than through whoever’s relationship the seller happened to start with.

Across the deals I’ve run, the gap between a direct-offer outcome and a competitive-process outcome on the same practice consistently produces several additional multiples of EBITDA on the headline — meaningful seven-figure improvements in total deal value. That’s the entire reason a sell-side advisor exists.

Normalized EBITDA: the number that gets multiplied

The multiple is one part of the equation. How that multiple actually pays out is another part — and increasingly in 2025-2026, the structure of the deal varies meaningfully between traditional 100 percent acquisitions with rollover equity at the platform level and the newer partnership or joint venture model where the buyer takes a majority stake (typically 60 to 80 percent) in the practice itself and the seller retains 20 to 40 percent with a defined buyout multiple at a future date.

Per MB Law Firm’s 2025 commentary on healthcare M&A trends, the partnership model has become increasingly common. For the deal-structure mechanics, see our PE pricing guide.

The EBITDA you multiply against is the other major variable, and it’s where most first-time sellers leave the most money on the table.

The number on your P&L is not the number a buyer will pay against. Normalized EBITDA is the figure after stripping out personal, one-time, and owner-specific expenses that the next owner won’t inherit. Buyers price your practice against the normalized number.

They will not normalize for you — their economic incentive runs the opposite direction.

Here are the add-back categories that survive most buyers’ financial scrutiny, ranked roughly by how common they are and how much they typically move the EBITDA number.

Owner compensation above market rate

The largest add-back in most vet practice sales. If you’re paying yourself $400,000 a year and the going rate for a hired medical director with your responsibilities is $200,000, the $200,000 difference is an add-back.

On a typical multi-doctor practice, this add-back alone can move EBITDA $100,000 to $250,000.

Family members on payroll at above-market pay

Spouse, kids, parents on the practice’s payroll. The add-back is the portion of their compensation that exceeds what an unrelated employee would earn in the same role.

Documentation matters — buyers will dig in.

Personal vehicle and travel expenses

Owner’s truck, family vehicles run through the practice, personal travel on practice cards. The add-back is whatever portion of the expense isn’t legitimately practice-related.

One-time legal and professional fees

Real estate disputes, divorce-related legal work, employment lawsuits that don’t recur, accounting work for prior-year cleanups. These come out cleanly if they’re truly one-time and documented.

Continuing education spending above industry norms

The benchmark is typically 1 to 1.5 percent of revenue. Anything above that — particularly when it includes the owner’s spouse or international travel — gets scrutinized as a discretionary lifestyle expense.

Owner’s personal insurance

Health, disability, life insurance run through the practice for the owner and family at premium levels. The add-back is the difference between what the owner pays and what an arms-length employee benefit would cost.

Excess marketing or vendor spending

Marketing expenses that exceed industry norms (typically 1 to 2 percent of revenue), particularly when they support an owner’s personal brand or non-recurring campaigns.

Properly documented normalization typically raises the EBITDA figure 15 to 30 percent above the raw P&L number. On a practice showing $620,000 of P&L EBITDA, a defensible normalized number might land at $810,000 — a 31 percent lift.

At a 10x multiple, that’s $1.9 million of additional sale price. That’s the gap that gets lost when owners walk into a sale anchored to the wrong number.

What buyers’ accountants will challenge

Add-backs that get rejected when the buyer’s accountants run their deep financial review (the industry calls it a Quality of Earnings audit) fall into a few common categories. Aggressive owner-comp add-backs that exceed reasonable market rates for the role.

CE expenses that look like family vacations. Family members on payroll without documented job responsibilities. “One-time” legal fees that recur across multiple years.

Marketing spends justified as one-time but reflected in normalized run-rate expense.

That financial review can adjust the final purchase price 3 to 10 percent in either direction. Common findings include revenue-recognition issues (services billed but not collected, deferred income), inventory mis-valuation (especially in mixed-animal or large-animal practices), and doctor productivity tracking that doesn’t tie to documented schedules.

Aggressive add-backs that get rejected often hurt more than just losing that one add-back — they damage the credibility of the entire normalization, which then gets discounted more broadly.

The right approach isn’t for the owner to commission their own version of this audit before going to market. It’s for your advisor to do a thorough pre-sale financial review on your side of the table — built around exactly the kind of scrutiny the buyers’ accountants will run, but on your side of the table, before any of those buyers ever see your numbers.

That gives us months to clean up anything that wouldn’t survive a deep audit: questionable add-backs, revenue recognition issues, inventory valuation, doctor productivity tracking that doesn’t quite tie. By the time the buyer’s accountants do their own version, everything that would have been a price-cutting finding has already been addressed.

That work is part of how we prepare practices for sale, and it’s almost always responsible for at least one multiplier point of additional sale value.

Specialty and ER hospitals trade at a premium

If you operate a specialty or emergency hospital — oncology, neurology, cardiology, surgical referral, 24-hour ER — your multiple range is meaningfully different from general practice.

The differential between specialty/ER hospitals and comparable general practices in 2025-2026 is typically 1 to 2.5 additional multiples of EBITDA, with the best referral-and-ER platforms occasionally reaching a 3-point premium over average GP. Three factors drive the spread.

First, margin profile. Specialty procedures price at a premium and face less direct competition than routine general practice.

Margins of 22 to 30 percent are common on well-run specialty hospitals, compared to 15 to 22 percent for GP.

Second, supply constraint. There aren’t enough board-certified specialists to staff every market.

You can’t easily build a new specialty hospital from scratch — the training pipeline is the bottleneck. Buyers value scarcity.

Third, referral economics. Specialty hospitals receive case flow from a constellation of referring general practitioners.

The relationships are sticky. The case volume is stable.

Buyers value predictability.

The most active specialty acquirers in 2026 are Ethos Veterinary Health (Brown Brothers Harriman-backed, more than 145 specialty and emergency hospitals across major U.S. metros), MedVet (multi-sponsor private equity, focused on large multi-specialty hospitals with full ER capabilities), and BluePearl (the strategic exception — Mars-owned rather than PE-backed, with more than 110 specialty and emergency hospitals across 30 states). Each of these groups pays at the top of the specialty range for hospitals that fit their target profile.

If you run a hybrid practice that includes specialty or emergency services alongside general practice, expect a blended multiple that weights toward the specialty range for the proportion of revenue and EBITDA coming from those services.

Geography moves multiples too

PE-backed buyers pay more for practices in markets they want to grow in. Sun Belt practices, suburban metros with high pet-ownership households, and markets with strong population growth attract more bidders and clear at higher multiples than comparable rural or stagnant-market practices, holding all other variables constant.

The geographic differential typically runs half a point to one and a half points of the multiple. A multi-doctor practice in suburban Austin, Charlotte, or Tampa will often attract competitive interest from five or more PE-backed bidders.

The same practice in a slower-growth rural market may attract two or three serious bidders.

The driver isn’t really the geography itself. It’s the level of competitive interest a practice generates, which is closely correlated with the location.

PE-backed groups have geographic priorities baked into their acquisition strategies — they’re building regional density, filling specific markets, or chasing demographic growth patterns. A practice that fits two or three of their target markets attracts more bidders.

More bidders means a higher clearing price.

If your practice is in a market that’s outside the primary geographic priorities of the major PE-backed groups, the competitive-process advantage matters even more. We’ve cleared meaningful multiples on practices in markets the major buyers wouldn’t have prioritized — but only because the structured process brought in regional acquirers and smaller PE-backed groups who valued the market more than the big players did.

What’s actually closing in 2025 and 2026

A few named transactions give shape to the current market.

Mars Veterinary Health acquired roughly 180 U.S. veterinary clinics during 2025, expanding its global network to approximately 3,200 sites, per Mordor Intelligence’s veterinary medicine market report. Mars is the strategic exception in this market — the world’s largest veterinary practice owner is family-owned (Mars, Incorporated), not PE-backed.

Its veterinary brands include Banfield Pet Hospital (more than 1,000 hospitals across the U.S. and Puerto Rico), VCA Animal Hospitals (more than 1,000 hospitals across the U.S., Canada, and Japan), and BluePearl (more than 110 specialty and emergency hospitals). Mars historically rebrands acquired practices over time more aggressively than the PE-backed groups do.

AmeriVet Veterinary Partners (PE-backed) announced on November 20, 2025 that it had acquired 14 new practices from Northeast Veterinary Partners, bringing AmeriVet’s U.S. network to 186 clinics, per coverage in Octus’s private credit research note.

National Veterinary Associates (owned by JAB Holdings, the European investment vehicle behind Krispy Kreme, Panera, and Pret a Manger) supports more than 1,500 companion animal practices, equine hospitals, and pet resorts worldwide as of late 2025.

Southern Veterinary Partners (PE-backed) operates more than 400 general practice hospitals across 28 states. VetCor (Harvest Partners-backed) operates more than 900 practices in the U.S. and Canada. PetVet Care Centers (KKR-backed) operates more than 450 general, specialty, and emergency hospitals across the U.S. Pathway Vet Alliance, which rebranded as Thrive Pet Healthcare, runs more than 400 hospitals across 37 states.

A useful framing for understanding this market: most major non-strategic vet practice buyers are PE-backed firms, and PE-backed firms generally preserve local practice branding rather than rebranding. The rebrand concern that many owners associate with selling to a “corporate” buyer mostly applies to Mars-owned VCA — the exception, not the rule.

Capstone Partners‘ April 2026 Pet Sector M&A Update flagged 18 pet sector deals in the first months of 2026, more than double the 8 deals tracked in the same window of 2025. Vet & Health accounted for half of those 2026 deals.

The expectation is that PE sponsor activity stays strong through the rest of 2026 and into 2027 as limited partners push for liquidity events deferred since the 2022 rate environment.

Hard dollar values for practice-level acquisitions are rarely disclosed publicly. For platform-level transactions — where PE sponsors sell entire consolidator portfolios or recapitalize through continuation vehicles — multiples sometimes leak through private credit commentary when the deal includes acquisition financing.

Recent platform recaps have frequently traded at high-teens EBITDA multiples. Those numbers describe the value of the platform as a whole, not the per-practice acquisition price the PE sponsor paid to build the platform.

The strategy is called “multiple arbitrage” — buy smaller practices at lower multiples, integrate them, then sell the combined entity at a higher multiple.

The regulatory layer that didn’t exist 3 years ago

Several states have introduced legislation directly targeting private equity-backed consolidators in healthcare and veterinary medicine. New York’s Assembly Bill 9042, North Carolina’s Senate Bill 570, and similar bills in other states are tightening corporate practice of medicine (CPOM) rules — the state laws that restrict who can own or control medical and veterinary practices. They limit certain management services organization (MSO) structures — the corporate entities that PE-backed groups use to own shared services across multiple practices — and they void some non-compete provisions.

None of these laws directly caps what a buyer can pay. What they do is change how the deal can be structured.

Rollover equity terms get adjusted to put more economic ownership at the clinical entity level. Non-competes get either shortened in geography and duration or traded for higher cash at close.

MSO structures get redesigned to satisfy new ownership thresholds. The legal commentary from Dechert and Holland & Knight covers the practical implications in detail.

For practice owners considering selling in 2026, the regulatory layer adds complexity to closing but doesn’t materially change what your practice is worth. It does affect what’s negotiable inside the deal — particularly around earnout protections, post-sale ownership percentages, and the geographic scope of any non-compete.

If you’re selling in a state with active CPOM legislation, expect your buyer’s legal team to spend more time on structure than they would have in 2022. Sophisticated PE-backed buyers are absorbing most of the friction in their own deal costs rather than discounting price.

Setting realistic expectations for your specific practice

For a solo owner-operator producing more than half of the practice’s revenue, the realistic 2026 direct-offer range is 4x to 6x normalized EBITDA. A properly run competitive process can lift that to 6x to 8x.

Pushing meaningfully above the 8x range typically requires building doctor production diversification before going to market — 12 to 24 months of associate hires and operational restructuring.

For a multi-doctor general practice with diversified production and decent management depth, the direct-offer range is 5.5x to 7.5x. The competitive-process range is 9x to 12x.

Where you land inside that range depends on growth rate, margin, geographic profile, and the quality of the process you run.

For a scaled multi-site operation or a specialty/ER hospital, the direct-offer range is 9x to 12x. The competitive-process range starts around thirteen and runs up from there.

The strongest specialty platforms in attractive geographies, run through structured competitive processes, occasionally clear at fourteen and above.

The expectation you don’t want to anchor on is the press-release headline. The 16x and 18x multiples that surface in industry coverage describe entire platforms changing hands at the PE sponsor level — not individual practices being added to those platforms.

Multiple arbitrage is the entire economic basis for the platform-level premiums. Those numbers don’t translate to what you’ll see as a single-practice seller.

“I knew that I would get the best value for my practice if I had a professional helping me. And it definitely turned out to be true that having Tom in my corner. I have zero doubt that I would not have gotten the value for my practice if I didn’t have him on my side as well as the ease of it. It was such an easy transition and he made the entire process very simple.”

— Sharon Gorman, Las Vegas, Nevada

What to do next

Most of what I’ve laid out here is the kind of thing I’d walk a vet through over dinner in the first hour of getting to know them. The data tells you the range.

What determines where you actually land is the process you run from here.

If you’re inside the 2-year window before you sell — and most of the vets who read this far are — there are two moves that mostly determine your outcome.

The first is getting an honest, defensible normalized EBITDA number documented before any buyer enters the conversation. Not built by your regular CPA in isolation unless they’ve personally been through major veterinary practice transactions before.

The vets who walk into a sale with that number properly documented and supported clear meaningfully more than the vets who anchor to the raw P&L. I’ve watched this play out enough times that I stop calling it a pattern and start calling it a rule.

The second is not signing exclusivity with the first PE-backed buyer who calls. They have a playbook.

The opening conversation mentions a number that gets your attention. They ask for 30 days exclusive to “complete diligence.” During those 30 days they find reasons the number needs to come down.

By the time you realize what’s happened, the other potential bidders have moved on with their year, and your leverage is gone.

A competitive process flips that dynamic. The same buyers who’d pay 6 times earnings when they’re the only ones at the table will pay nine, ten, sometimes twelve when they know they’re competing — and when they know the seller has the alternative of walking to the next bidder.

If you want a defensible estimate of what your specific practice would clear in a real competitive process, that’s what we built our work to find out.

Get a Free Practice Value Estimate →

We pull your numbers ourselves, build the normalized EBITDA properly, run the pre-sale financial review that surfaces and fixes anything a buyer’s accountants would have caught, identify the right group of PE-backed buyers for your specific profile and geography, and send you back a defensible value range with the math behind it. The estimate is free and there’s no obligation to engage further.

The Transitions Elite engagement model is success-based — no upfront fees, no retainer. We only get paid when a deal closes, and only out of the value our process delivers above what you would have realized on your own.

---

Further reading

These are the related TE resources I’d point any vet considering a sale toward. Each one goes deep on a single dimension of the decision.

• How much private equity is paying for veterinary practices — the PE business model, the four components of any PE-backed offer, and why the headline number rarely equals the cash check.
• Veterinary practice consolidators directory — the verified directory of every major PE-backed and strategic buyer operating in 2026, with ownership, scale, and target profile per buyer.
• How to sell a veterinary practice — the 7-step process from advisor engagement to closing, including tax considerations and post-sale realities.
• Selling your veterinary practice to NVA — the buyer-specific deep dive on National Veterinary Associates and JAB Holdings.
• Our practice sale results — case studies and outcomes across the practices we’ve represented.
• About Transitions Elite — the team, the methodology, and the firm’s track record.

Frequently asked questions

What multiple of EBITDA do veterinary practices sell for in 2026?

Most vet practices change hands somewhere between 5 and 13 times normalized EBITDA in 2026. Direct, single-bidder offers from one buyer typically come in meaningfully lower than what the same practice would clear through a competitive process.

Specialty and emergency hospitals run higher than comparable general practices. Multiples cleared through competitive bidding processes consistently land at the upper end of the range — often several multiples of EBITDA above what the same buyer would offer in a direct conversation.

What is normalized EBITDA?

Normalized EBITDA is your practice’s earnings after stripping out personal expenses you run through the practice and one-time costs the next owner won’t inherit. Common add-backs include owner compensation above fair market rate, personal vehicles, family members on payroll above market comp, one-time legal fees, and discretionary continuing education spending above industry norms.

Buyers price your practice against normalized EBITDA, not the raw number on your P&L. Properly documented normalization typically raises the figure 15 to 30 percent above the tax-return number.

Why do specialty veterinary practices sell for higher multiples than general practices?

Specialty and emergency hospitals generally trade at 1 to 2.5 additional multiples of EBITDA of EBITDA above comparable general practices in 2025-2026, with top referral and emergency platforms occasionally reaching a 3-point premium. Three drivers: higher margin profiles (specialty procedures price at a premium and have less direct competition), constrained supply (specialists are scarce and you can’t easily build a new specialty hospital), and reliable referral economics (referring GPs keep the case flow steady).

Ethos Veterinary Health, MedVet, and BluePearl are the most active specialty-focused acquirers.

What raises a veterinary practice’s EBITDA multiple before sale?

Five things move the multiple measurably. Bringing your own clinical production below half of the practice’s total.

Building real management depth, especially a capable practice manager. Three consecutive years of revenue growth above 5 percent.

EBITDA margin sustained above 18 percent. And the largest variable: running a competitive sale process instead of accepting a direct offer.

Each of the first four can move the multiple a point or two with 12 to 24 months of focused prep. The fifth typically moves it 3 to 7 additional multiples of EBITDA on its own.

How do 2026 multiples compare to the 2021 peak?

Lower than peak but recovering. Per industry M&A coverage of the 2021-2022 peak, practice multiples reached 12 to 18 times EBITDA before compressing as interest rates rose.

Capstone Partners describes 2024 as the trough year. The 2025 to early 2026 window shows clear recovery, with practice multiples climbing roughly 1 to 3 additional multiples of EBITDA off the 2024 lows.

Specialty hospitals held value better through the downturn than general practice.

What happens when a buyer’s accountants review my practice’s numbers before closing?

Buyers run a deep financial review (the industry calls it a Quality of Earnings audit) on any practice sale above about $5 million. Their accountants scrutinize your add-backs, revenue recognition, inventory valuation, and doctor productivity tracking.

The findings adjust the final purchase price 3 to 10 percent in either direction. The single best way to protect against an unwelcome surprise is to have an advisor on your side of the table do a thorough pre-sale financial review during preparation, so anything that wouldn’t survive scrutiny gets cleaned up before the buyer ever sees your numbers.

Do new state regulations affect what my veterinary practice will sell for?

Indirectly, yes. New York’s AB 9042, North Carolina’s SB 570, and similar bills in other states are tightening corporate-practice-of-medicine rules.

They limit certain management services organization structures and void some non-compete provisions. None of these laws directly caps purchase price.

They do change how PE-backed buyers structure deals, particularly around rollover equity, post-sale ownership terms, and non-compete enforceability. Sophisticated buyers are adapting their structures rather than discounting price, so the economic impact on sellers in regulated states is generally modest.

Do geographic factors affect veterinary practice multiples?

Yes. Sun Belt practices, suburban metros with high pet-ownership households, and markets with strong population growth tend to attract more PE-backed bidders and clear at higher multiples than comparable rural or stagnant-market practices.

The differential typically runs half a point to one and a half points of the multiple based on geography alone, holding all other variables constant. The bigger driver isn’t the geography itself but the level of competitive interest a practice attracts — which is closely correlated with location.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion — VSOs Under Increasing Pressure.” 2025. octus.com
3. QuantPillar. “2025-2026 Private Market Valuation Multiples.” quantpillar.com
4. Mordor Intelligence. “Veterinary Medicine Market.” mordorintelligence.com

Veterinary practice operations, benchmarks, and profession data

5. iVET360. “Understanding Your Animal Hospital’s EBITDA.” ivet360.com
6. Owner Exchange. “Veterinary Clinic Profitability Insights.” ownerexchange.com
7. AVMA. “Just released: AVMA data and insights on the veterinary profession.” avma.org

Legal and regulatory analysis

8. Dechert LLP. “Healthcare Investments Flash Alert — Latest Developments.” 2025. dechert.com
9. Holland & Knight. “Q1 Recap on Proposed Legislation Affecting Healthcare Consolidation.” 2026. hklaw.com